



For Immediate Release: Friday, September 24, 2004

## **NEWS RELEASE**

Contact: Howard Root, CEO  
James Hennen, CFO  
Vascular Solutions, Inc.  
(763) 656-4300

### **VASCULAR SOLUTIONS ANNOUNCES 510(K) CLEARANCE FOR LANGSTON DUAL LUMEN PIGTAIL CATHETER**

MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration for the Langston dual lumen pigtail catheter. The Langston catheter is a two-lumen diagnostic catheter indicated for use in the simultaneous measurement of pressures from two locations in the arterial system. Receipt of the 510(k) clearance will allow sales of the Langston catheter to commence in the U.S. through Vascular Solutions' direct sales force.

"This clearance and our impending launch of the Langston catheter continue Vascular Solutions' strategy of delivering clinically unique products for Interventional Cardiology and Interventional Radiology," commented Howard Root, Chief Executive Officer of Vascular Solutions. "The Langston catheter offers simultaneous accuracy and precise responsiveness in measuring intra-arterial pressure gradients, which is often used in diagnosing valvular disease. We estimate that the market opportunity for this unique catheter is approximately \$10 million annually, and that our Langston catheter is the only pigtail catheter available on the U.S. market today that can be used to simultaneously measure differential intravascular pressures," Mr. Root added.

The patent pending design of the Langston catheter was developed by Mr. Phil Langston, Cath Lab Manager of Tulsa Regional Medical Center in Tulsa, Oklahoma. The design has been exclusively licensed to Vascular Solutions on a worldwide basis.

#### **About Vascular Solutions**

Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within Interventional Radiology and Interventional Cardiology. New products introduced in the second half of 2003 include the Vari-Lase™ endovenous laser procedural kit for the treatment of varicose veins, the D-Stat Dry™ hemostatic bandage for the rapid control of topical bleeding, the D-Stat Radial™ hemostat band for the control of bleeding following catheterizations utilizing the radial artery in the wrist, and the Pronto™ extraction catheter for the mechanical extraction of soft thrombus. The Company's other products include the Duett™ sealing device to rapidly seal the puncture site following catheterization procedures, the D-Stat® Flowable hemostat for the local management of active bleeding, and the Acolysis® intravascular therapeutic ultrasound product which is sold in international markets for the treatment of peripheral occlusive arterial disease.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those

discussed in our Annual Report on Form 10-K for the year ended December 31, 2003 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with our limited operating history, need for adoption of our new products, lack of profitability, exposure to possible intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to [www.vascularsolutions.com](http://www.vascularsolutions.com).  
# # #